← Human Trials & Peer-Reviewed Studies
Acute negative affect relief from smoking depends on the affect situation and measure but not on nicotine.
Plain-language guide to PMID 20132927 (2010): randomized controlled trial of Therapeutic nicotine (patch, non-peptide).
Key Facts
- PMID
- 20132927
- Journal
- Biological psychiatry
- Year
- 2010
- Study type
- Randomized Controlled Trial
- Authors
- Perkins KA et al. (5 authors)
- DOI
- 10.1016/j.biopsych.2009.12.017
What This Study Did, in Plain Language
What Was Tested
The paper reports a study of Therapeutic nicotine (patch, non-peptide), published as a randomized controlled trial.
Smoking acutely relieves negative affect (NA) due to smoking abstinence but may not relieve NA from other sources, such as stressors.
Who Took Part
PubMed indexes the participants as adults, both men and women.
All subjects rated their level of NA and positive affect on several measures (Mood Form, Positive and Negative Affect Scale, Stress-Arousal Checklist, and State-Trait Anxiety Inventory-state).
How the Study Was Run
In design terms this was a randomized study.
The participants were allocated by chance, so the Therapeutic nicotine (patch, non-peptide) group and the comparison group should start out alike.
Dependent smokers (n = 104) randomly assigned to one of three smoking conditions (nicotine or denicotinized cigarettes, or no smoking) completed four negative mood induction procedures (one per session): 1) overnight smoking abstinence, 2) challenging computer task, 3) public speech preparation, and 4) watching negative mood slides.
A fifth session involved a neutral mood control.
The two smoking groups took four puffs on their assigned cigarette and then smoked those same cigarettes ad libitum during continued mood induction.
They also rated craving and withdrawal.
What Was Measured
Topics PubMed links to this paper include Affect, Anxiety, Executive Function, Nicotine, Nicotinic Agonists, Reinforcement, Psychology and Reward.
What This Means in Plain Language
The paper is a randomized study of Therapeutic nicotine (patch, non-peptide).
The abstract goes on to report its results in about 7 sentences; this page does not restate them, so read the paper for the findings and their limits.
The publication is from 2010 (Biological psychiatry), a journal based in United States.
More context: the Therapeutic nicotine (patch, non-peptide) compound page, all human trials.
Our Notes on the Compound
Therapeutic nicotine (patch, non-peptide): Pure nicotine as a signaling tool, separated from smoking and vaping.
Related Pages
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.